Evidence map›Paper›PMID 33425074›Full record

ArticleEuropean journal of integrative medicine2021

Network pharmacology-based analysis of Zukamu granules for the treatment of COVID-19.

Yijia Zeng, Guanhua Lou, Yuanyuan Ren, Tingna Li, Xiaorui Zhang, Jin Wang, Qinwan Huang

Abstract read
In one paragraph

Article in European journal of integrative medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yijia ZengCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, China.
Guanhua LouCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, China.
Yuanyuan RenCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, China.
Tingna LiCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, China.
Xiaorui ZhangCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, China.
Jin WangCollege of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, China.
Qinwan HuangCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionZukamu granules may play a potential role in the fight against the Coronavirus, COVID-19. The purpose of this study was to explore the mechanisms of Zukamu granules using network pharmacology combined with molecular docking.

methodsThe Traditional Chinese Medicine systems pharmacology (TCMSP) database was used to filter the active compounds and the targets of each drug in the prescription. The Genecards and OMIM databases were used for identifying the targets related to COVID-19. The STRING database was used to analyze the intersection targets. Compound - target interaction and protein-protein interaction networks were constructed using Cytoscape to decipher the anti-COVID-19 mechanisms of action of the prescription. The Kyoto Encyclopedia of Genes and Genome (KEGG) pathway and Gene Ontology (GO) enrichment analysis was performed to investigate the molecular mechanisms of action. Finally, the interaction between the targets and the active compounds was verified by molecular docking technology.

resultsA total of 66 targets were identified. Further analysis identified 10 most important targets and 12 key compounds. Besides, 1340 biological processes, 43 cell compositions, and 87 molecular function items were obtained (

conclusionAnalysis of the constructed pharmacological network results allowed for the prediction and interpretation of the multi-constituent, multi-targeted, and multi-pathway mechanisms of Zukamu granules as a potential source for supportive treatment of COVID-19.

Indexed as

ALB, Serum AlbuminBP, Biological ProcessCASP3, Caspase-3CC, Cell CompositionCCND1, Cyclin D1Covid-19COVID-19, Corona Virus Disease 2019EGFR, Epidermal Growth Factor ReceptorFOS, C-FOSGO, Gene OntologyIL-6, Interleukin- 6INS, InsulinKEGG, Kyoto Encyclopedia of Genes and GenomeMAPK8, Mitogen Activated Protein Kinase 8MF, Molecular FunctionMolecular dockingMYC, Muscarinic Acetylcholine ReceptorNetwork pharmacologyPPI, Protein-Protein InteractionPulmonary fibrosisTCMSP, Traditional Chinese Medicine systems pharmacologyVEGFA, Vascular Endothelial Growth Factor-AZukamu granule

Identifiers

PMID33425074
PMCPMC7778372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.